Targeting the inflammatory response to treat post-traumatic anxiety and depression.
Targeting the inflammatory response to treat post-traumatic anxiety and depression.
批准号:
10350545
负责人:
Todd D Gould
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-01 至 2022-06-30
关键词:
AcuteAffectAfghanistanAnti-Anxiety AgentsAnti-Inflammatory AgentsAntidepressive AgentsAnxietyAnxiety DisordersBehaviorBehavioralBiological MarkersBrainCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCell physiologyCellsCellular ImmunityCellular StressClinicalDataDepressive disorderDevelopmentDiagnosisDiseaseElementsEmotionalEmotional StressEncephalitisEventExposure toFlow CytometryFunctional disorderGeneral PopulationGlucocorticoid ReceptorGoalsGreen Fluorescent ProteinsHomingHumoral ImmunitiesImmuneImmune TargetingImmune responseImmune systemImmunomodulatorsIndividualInflammationInflammatoryInflammatory ResponseInterleukin-6InterventionIraqKnowledgeLeadLiteratureMeasuresMediatingMemoryMental DepressionMental disordersMicrogliaMusNervous System PhysiologyNeuraxisOrganPathologyPatientsPeripheralPhysiologicalPlasmaPost-Traumatic Stress DisordersPredispositionPrevalenceProcessPropertyPsychological StressPsychoneuroimmunologyPublishingResearchRiskSideSiteSoldierSourceStressT cell therapyT-Cell ActivationT-Cell Activation PathwayT-LymphocyteT-Lymphocyte SubsetsTNF geneTestingTherapeuticTherapeutic EffectTherapeutic InterventionTissuesTransgenic OrganismsTravelTreatment EfficacyValidationVeteransWarWild Type MouseWorkbasebehavior influencebehavioral outcomebehavioral responsebiological adaptation to stresscell typecomorbiditycytokinecytotoxic CD8 T cellsdepressive symptomsdesigneffective therapyemotion dysregulationemotion regulationemotional behaviorexperienceglucocorticoid receptor alphaimmune functionimprovedinnovationmouse modelneurochemistryneuroinflammationneutralizing antibodynew therapeutic targetnovelnovel strategiesnovel therapeutic interventionpatient subsetspre-clinicalpreclinical studypredictive modelingpreventprogramsprotective effectpsychologicpsychological traumareceptor sensitivityreconstitutionresilienceresponsesymptomatic improvementsystemic inflammatory responsetherapeutic evaluationtranscriptometranscriptome sequencingtraumatic eventtraumatic stresstreatment of anxiety disorderstreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The stress of deployment and exposure to traumatic events puts soldiers at a greater risk than the
general public for the development of psychological disorders, including anxiety and depression, as well as
post-traumatic stress disorder. These mental disorders occur with high comorbidity, and the prevalence of
these conditions in Veterans of the recent Iraq and Afghanistan wars (OEF/OIF) is a concern of high
significance for the VA. While a number of therapeutic options are available for the treatment of these
conditions, they are marginally responsive to classical anxiolytic and antidepressant treatment when they
develop as a consequence of traumatic stress exposure. Extensive research in the field of
psychoneuroimmunology has indicated that these conditions are associated with dysregulated immune
function, manifested as increased systemic inflammation and altered cellular and humoral immunity; which is
believed to be a mechanism underlying the pathophysiology of these disorders. Our previous studies and
others in the literature have shown that T cells are responsive to traumatic stress exposure and can influence
behavioral responses of mice, conferring either resilience or susceptibility to stress depending upon the type of
T cell and the cytokine milieu. Our preliminary results strongly indicate that CD8+ cytotoxic T cells are a major
source of systemic and brain inflammation and promote susceptibility to develop maladaptive behavioral
responses to stress. On the other side, our recently published study indicates that CD4+ T cells improve
behavioral responses to stress, perhaps by reducing inflammation, in line with the work of others in the field.
Thus, the overall objective of this application is to test, in a pre-clinical mouse model, the therapeutic efficacy
of treating anxiety and depression by reducing inflammatory processes triggered by traumatic stress exposure.
We propose to specifically manipulate CD4+ and CD8+ T cell mediated immunity to reduce systemic and brain
inflammation, and improve behavioral outcomes. We propose 3 specific aims:
Specific Aim 1 will identify mechanisms by which traumatic stress alters T cell functions by examining
homing properties of CD4+ and CD8+ T cells in response to stress, and whether they develop alterations in
glucocorticoid receptor sensitivity. To accomplish this we will reconstitute T cell deficient Rag2-/- mice with T
cell subsets derived from green fluorescent protein (GFP) expressing mice, allowing for the tracking and
identification of T cells in multiple tissues- including the brain. Additionally, we will conduct transcriptome
analysis of T cells of stressed vs non-stressed wild type mice using RNA-sequencing (RNAseq) to identify
pathways of T cell activation induced by traumatic stress. Specific Aim 2 is designed to determine the effects
on behavior of manipulating CD4+ and CD8+ T cells in stressed mice. The approach will involve a)
reconstitution in Rag2-/- mice with CD4+ or CD8+ T cells from stressed wild type mice, and b) the use of
neutralizing antibodies against CD4+ or CD8+ T cells in stressed wild type mice. Following treatment, mice will
be assessed for anxiety, behavioral despair, and startle reactivity as measures of emotional behavior. Specific
Aim 3 will study the effects of manipulating CD4+ and CD8+ T cells on peripheral and brain inflammation.
Plasma and tissue cytokine levels will be evaluated in peripheral tissue and brain; neuroinflammation will be
further assessed using microglial cultures and flow cytometry. Finally, to determine if CD8+ T cells confer their
effects through the actions of the cytokines TNF-α and IL-6. We will also block these cytokines in the presence
of CD8+ T cells and determine if there is a reduction in neuroinflammation.
The studies in this application are expected to provide proof of concept that CD8+ T cells are the main
source of inflammatory processes triggered by traumatic stress exposure and it is possible to improve
emotional regulation by targeting these cells. Furthermore, they may help identify unique mechanisms of stress
induced T cell activation and novel targets of therapeutic intervention to treat stress related mental disorders.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Estradiol treatment of stress-related psychiatric disorders in Veterans
-
批准号:10484783
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:Todd D Gould
-
依托单位:
Hydroxynorketamine for the Treatment of PTSD and Anhedonia
-
批准号:10626710
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Todd D Gould
-
依托单位:
Hydroxynorketamine for the Treatment of PTSD and Anhedonia
-
批准号:9561714
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Todd D Gould
-
依托单位:
Hydroxynorketamine for the Treatment of PTSD and Anhedonia
-
批准号:10046271
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Todd D Gould
-
依托单位:
Hydroxynorketamine for the Treatment of PTSD and Anhedonia
-
批准号:10292948
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Todd D Gould
-
依托单位:
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment
-
批准号:9502214
-
项目类别:
-
资助金额:$15.34万
-
财政年份:2017
-
负责人:Todd D Gould
-
依托单位:
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment
-
批准号:10553628
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2016
-
负责人:Todd D Gould
-
依托单位:
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment
-
批准号:10056004
-
项目类别:
-
资助金额:$66.67万
-
财政年份:2016
-
负责人:Todd D Gould
-
依托单位:
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment
-
批准号:10322395
-
项目类别:
-
资助金额:$63.33万
-
财政年份:2016
-
负责人:Todd D Gould
-
依托单位:
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment
-
批准号:9417095
-
项目类别:
-
资助金额:$47.98万
-
财政年份:2016
-
负责人:Todd D Gould
-
依托单位:
Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment
-
批准号:9314708
-
项目类别:
-
资助金额:$9.24万
-
财政年份:2016
-
负责人:Todd D Gould
-
依托单位:
An NMDA Glycine Site Antagonist for the Treatment of Major Depressive Disorder
-
批准号:8583778
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2013
-
负责人:Todd D Gould
-
依托单位:
Role of Brain Estradiol in the Treatment of Male Depression and Anxiety
-
批准号:8641438
-
项目类别:
-
资助金额:$18.98万
-
财政年份:2013
-
负责人:Todd D Gould
-
依托单位:
Role of Brain Estradiol in the Treatment of Male Depression and Anxiety
-
批准号:8512027
-
项目类别:
-
资助金额:$23.94万
-
财政年份:2013
-
负责人:Todd D Gould
-
依托单位:
An NMDA Glycine Site Antagonist for the Treatment of Major Depressive Disorder
-
批准号:8731972
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2013
-
负责人:Todd D Gould
-
依托单位:
Gonadal Hormones and Depression:The Role of Mood Disorder Risk Gene CACNA1C
-
批准号:8093587
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2011
-
负责人:Todd D Gould
-
依托单位:
Gonadal Hormones and Depression:The Role of Mood Disorder Risk Gene CACNA1C
-
批准号:8257914
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2011
-
负责人:Todd D Gould
-
依托单位:
Suicide Endophenotypes and Molecular Mechanisms of Lithium Action
-
批准号:8004820
-
项目类别:
-
资助金额:$38.85万
-
财政年份:2010
-
负责人:Todd D Gould
-
依托单位:
Suicide Endophenotypes and Molecular Mechanisms of Lithium Action
-
批准号:8452200
-
项目类别:
-
资助金额:$35.74万
-
财政年份:2010
-
负责人:Todd D Gould
-
依托单位:
Suicide Endophenotypes and Molecular Mechanisms of Lithium Action
-
批准号:8105498
-
项目类别:
-
资助金额:$37.22万
-
财政年份:2010
-
负责人:Todd D Gould
-
依托单位:
海外基金